The Joint Programme continued to play a leading role in strategically convening scientists, communities and multisectoral stakeholders, including through international fora and expert reports, to ensure the most up-to date evidence and innovations for HIV testing, treatment, care, support integrated services and develop normative, strategic and implementation guidance.

Supporting countries in aligning their national policies and programmes with evidence-based guidelines remained a central focus of the Joint Programme’s work in 2022. The Joint Programme’s work in promoting the adoption and implementation of global guidance for the best HIV treatment to be accessible to all who need it has achieved concrete results. More than 95% of countries now implement a “treat all” approach.

Find more details in the Results report.


UBRAF Indicator progress on HIV treatment (RA 2)

Guidance for integrated service delivery of HIV and comorbidities is in development to meet the respective 2023 milestones next year.

Implementation of the 2021 WHO Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring was supported and will be measured through Global AIDS Monitoring reporting (available mid-2023).

Number of countries that implemented recommended WHO-preferred first-line ARV regimen for treatment initiation will be measured through the Global AIDS Monitoring reporting (available mid-2023).

Number of countries that have adapted shorter rifamycin-based regimens for TB preventive treatment will be measured through Global AIDS Monitoring (available mid-2023).

Further information on the 2022–2026 UBRAF Indicators definition and results can be found in the Indicator Scorecard.